Basic Principles of Drug Discovery and Development,
Edition 2Editors: By Benjamin E. Blass
Conformance
-
PDF/UA-1
-
The publication was certified on 20250728
-
For queries regarding accessibility information, contact [email protected]
Ways Of Reading
-
This e-publication is accessible to the full extent that the file format and types of content allow, on a specific reading device, by default, without necessarily including any additions such as textual descriptions of images or enhanced navigation.
Navigation
-
The contents of the PDF have been tagged to permit access by assistive technologies as per PDF-UA-1 standard.
-
Page breaks included from the original print source
Additional Accessibility Information
-
The language of the text has been specified (e.g., via the HTML or XML lang attribute) to optimise text-to-speech (and other alternative renderings), both at the whole document level and, where appropriate, for individual words, phrases or passages in a different language.
Note
-
This product relies on 3rd party tooling which may impact the accessibility features visible in inspection copies. All accessibility features mentioned would be present in the purchased version of the title.
Basic Principles of Drug Discovery and Development presents the multifaceted process of identifying a new drug in the modern era, which requires a multidisciplinary team approach with input from medicinal chemists, biologists, pharmacologists, drug metabolism experts, toxicologists, clinicians, and a host of experts from numerous additional fields. Enabling technologies such as high throughput screening, structure-based drug design, molecular modeling, pharmaceutical profiling, and translational medicine are critical to the successful development of marketable therapeutics.
Given the wide range of disciplines and techniques that are required for cutting edge drug discovery and development, a scientist must master their own fields as well as have a fundamental understanding of their collaborator’s fields. This book bridges the knowledge gaps that invariably lead to communication issues in a new scientist’s early career, providing a fundamental understanding of the various techniques and disciplines required for the multifaceted endeavor of drug research and development. It provides students, new industrial scientists, and academics with a basic understanding of the drug discovery and development process. The fully updated text provides an excellent overview of the process and includes chapters on important drug targets by class, in vitro screening methods, medicinal chemistry strategies in drug design, principles of in vivo pharmacokinetics and pharmacodynamics, animal models of disease states, clinical trial basics, and selected business aspects of the drug discovery process.
Key Features
- Provides a clear explanation of how the pharmaceutical industry works, as well as the complete drug discovery and development process, from obtaining a lead, to testing the bioactivity, to producing the drug, and protecting the intellectual property
- Includes a new chapter on the discovery and development of biologics (antibodies proteins, antibody/receptor complexes, antibody drug conjugates), a growing and important area of the pharmaceutical industry landscape
- Features a new section on formulations, including a discussion of IV formulations suitable for human clinical trials, as well as the application of nanotechnology and the use of transdermal patch technology for drug delivery
- Updated chapter with new case studies includes additional modern examples of drug discovery through high through-put screening, fragment-based drug design, and computational chemistry
About the author
By Benjamin E. Blass, Temple University School of Pharmacy, Philadelphia, PA, USA
9780123820310; 9780081010112; 9780080466170
Upper level undergraduate students and graduate students interested in drug discovery research, chemistry, biology, pharmacology, biochemistry, toxicology, formulations, discovery/development of new therapeutic agents; pharmaceutical industry; FDA, public policy groups interested in influencing the pharmaceuticals industry; business analysts, entrepreneurs, venture capitalists interested in investing in the pharmaceuticals industry